PSC-derived NK Cells
Cancer (unspecified)
Pre-clinicalActive
Key Facts
About HebeCell
HebeCell is a private, pre-clinical stage biotech developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer using its proprietary ProtoNK™ manufacturing platform. Founded by seasoned stem cell scientists, the company aims to overcome limitations of autologous cell therapies by creating a scalable, cost-effective source of potent NK cells. In addition to its internal therapeutic pipeline, HebeCell offers cryopreserved cells, custom cell production, and contract manufacturing services to generate early revenue and support platform validation.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |